Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 22;14:2927–2935. doi: 10.2147/DDDT.S254466

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 He et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Triptolide restrained the cell cycle in IL22-stimulated HaCaT via upregulating miR-181b-5p. HaCaT cells were transfected with miR-181b-5p antagomir and exposed to 10 μM triptolide for 24 h, and then treated with 100 ng/mL of IL22 for 24 h. (A and B) Cell cycle staging was measured by flow cytometry. (C) Expression levels of P21, CYCLIN E1 and CDK2 in cells were detected with Western blotting. (D–F) The relative expressions of P21, CYCLIN E1 and CDK2 in cells were quantified via normalization to BETAACTIN. **P < 0.01, compared with the control group. ^##P < 0.01, compared with the 100 ng/mL IL22 group. ^{^}P < 0.05, ^{^^}P < 0.01 compared with IL22 + triptolide group.